Correction: Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial (Journal of the American College of Cardiology (2017) 69(11) (1372–1382), (S0735109717301924) (10.1016/j.jacc.2016.12.031));Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial

Journal of the American College of Cardiology

Volumn 69, Issue 11, 2017, Pages 1372-1382

  De Caterina, Raffaele ^a   Renda, Giulia ^a   Carnicelli, Anthony P ^b   Nordio, Francesco ^b   Trevisan, Marco ^b   Mercuri, Michele F ^c   Ruff, Christian T ^b   Antman, Elliott M ^b   Braunwald, Eugene ^b   Giugliano, Robert P ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

anticoagulation; atrial fibrillation; edoxaban; NOACs; valvular heart disease; warfarin

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGE; AGED; ANTICOAGULANT THERAPY; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; ATRIAL FIBRILLATION; BIOPROSTHESIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CHADS2 SCORE; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MITRAL VALVE REGURGITATION; RANDOMIZED CONTROLLED TRIAL; SEX; VALVULAR HEART DISEASE; VALVULOPLASTY; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; EMBOLISM; MIDDLE AGED; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; EMBOLISM; FEMALE; HEART VALVE DISEASES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; STROKE; THIAZOLES; WARFARIN;

EID: 85015243810     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.01.002     Document Type: Erratum

References (27)

1. 1 Soler-Soler, J., Galve, E., Worldwide perspective of valve disease. Heart 83 (2000), 721–725.
2. 2 Nkomo, V.T., Gardin, J.M., Skelton, T.N., Gottdiener, J.S., Scott, C.G., Enriquez-Sarano, M., Burden of valvular heart diseases: a population-based study. Lancet 368 (2006), 1005–1011.
3. 3 Iung, B., Vahanian, A., Epidemiology of acquired valvular heart disease. Can J Cardiol 30 (2014), 962–970.
4. 4 Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129 (2014), 837–847.
5. 5 De Caterina, R., Camm, A.J., What is ‘valvular’ atrial fibrillation? A reappraisal. Eur Heart J 35 (2014), 3328–3335.
6. 6 Kannel, W.B., Wolf, P.A., Benjamin, E.J., Levy, D., Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82 (1998), 2N–9N.
7. 7 Menezes, A.R., Lavie, C.J., DiNicolantonio, J.J., et al. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc 88 (2013), 394–409.
8. 8 Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
9. 9 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
10. 10 Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
11. 11 Kirchhof, P., Ammentorp, B., Darius, H., et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace 16 (2014), 6–14.
12. 12 Molteni, M., Polo Friz, H., Primitz, L., Marano, G., Boracchi, P., Cimminiello, C., The definition of valvular and non-valvular atrial fibrillation: results of a physicians’ survey. Europace 16 (2014), 1720–1725.
13. 13 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
14. 14 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
15. 15 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
16. 16 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
17. 17 Ruff, C.T., Giugliano, R.P., Antman, E.M., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48). Am Heart J 160 (2010), 635–641.
18. 18 Schulman, S., Kearon, C., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005), 692–694.
19. 19 Avezum, A., Lopes, R.D., Schulte, P.J., et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 132 (2015), 624–632.
20. 20 Ezekowitz, M.D., Nagarakanti, R., Noack, H., et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 134 (2016), 589–598.
21. 21 Breithardt, G., Baumgartner, H., Berkowitz, S.D., et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 35 (2014), 3377–3385.
22. 22 Vahanian, A., Alfieri, O., Andreotti, F., et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33 (2012), 2451–2496.
23. 23 Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013), 1206–1214.
24. 24 Jaffer, I.H., Stafford, A.R., Fredenburgh, J.C., Whitlock, R.P., Chan, N.C., Weitz, J.I., Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc, 4, 2015, e002322.
25. 25 De Caterina, R., Camm, J.A., Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. Europace 18 (2015), 6–11.
26. 26 Gupta, D.K., Shah, A.M., Giugliano, R.P., et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF–TIMI 48. Eur Heart J 35 (2014), 1457–1465.
27. 27 Puskas, J., Gerdisch, M., Nichols, D., et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 147 (2014), 1202–1210 discussion 1210–1.